Lab
Reliance Diagnostics LLC
Reliance Diagnostics LLC was paid $846K by Medicaid between Jul 2021 and Oct 2024, across 70 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 82% of everything it billed.
33Billing provider infoRELIANCE DIAGNOSTICS LLC
MIAMI, FL 33186
MIAMI, FL 33186
33aNPI1528653334assigned 03/03/2021
33bProvider typeClinical Medical Laboratory
28Total paid$846K
24GClaims39,303
24DCodes billed70
24AFirst – last monthJul 2021 – Oct 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Florida
Rank by total paid#47 of 225
Median peer was paid$74K
This provider vs. median12×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2021 | 3,032 | $35K | |
| 2022 | 19,352 | $452K | |
| 2023 | 10,228 | $285K | |
| 2024incomplete | 6,691 | $74K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 82% | 10,233 | 8,501 | $695K |
| P9603 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated miles actually travelled | 4.3% | 5,577 | 4,559 | $37K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 2.1% | 8,142 | 6,687 | $17K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 2.1% | 610 | 588 | $17K |
| 81321 | <1% | 268 | 268 | $7K | |
| 87428 | <1% | 288 | 144 | $5K | |
| 81320 | <1% | 388 | 388 | $5K | |
| 81238 | <1% | 172 | 172 | $4K | |
| 81307 | <1% | 129 | 129 | $4K | |
| 81311 | <1% | 290 | 290 | $4K | |
| 81185 | <1% | 73 | 73 | $3K | |
| 81175 | <1% | 88 | 88 | $3K |
58 more codes
| 81191 | <1% | 291 | $3K | |
| 81334 | <1% | 204 | $3K | |
| 81192 | <1% | 197 | $3K | |
| 81351 | <1% | 73 | $3K | |
| 81419 | <1% | 85 | $2K | |
| 81324 | <1% | 62 | $2K | |
| 81302 | <1% | 61 | $2K | |
| 81249 | <1% | 120 | $2K | |
| 81339 | <1% | 203 | $2K | |
| 81345 | <1% | 243 | $2K | |
| 81235 | <1% | 91 | $1K | |
| 81233 | <1% | 188 | $1K | |
| 81236 | <1% | 105 | $1K | |
| 81309 | <1% | 166 | $1K | |
| 81189 | <1% | 73 | $1K | |
| 81223 | <1% | 83 | $978.04 | |
| 81275 | <1% | 73 | $757.52 | |
| 81256 | <1% | 238 | $743.25 | |
| 81312 | <1% | 104 | $645.54 | |
| 81171 | <1% | 87 | $645.54 | |
| 81183 | <1% | 105 | $645.54 | |
| 81177 | <1% | 87 | $645.54 | |
| 81178 | <1% | 88 | $645.54 | |
| 81329 | <1% | 104 | $645.54 | |
| 81188 | <1% | 105 | $645.54 | |
| 81284 | <1% | 105 | $645.54 | |
| 81179 | <1% | 105 | $645.54 | |
| 81344 | <1% | 105 | $645.54 | |
| 81182 | <1% | 105 | $645.54 | |
| 81181 | <1% | 105 | $645.54 | |
| 81271 | <1% | 105 | $645.54 | |
| 81343 | <1% | 104 | $645.54 | |
| 81180 | <1% | 105 | $645.54 | |
| 81194 | <1% | 83 | $507.91 | |
| G2024 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a snf or by a laboratory on behalf of a hha, any specimen source | <1% | 6,476 | $458.28 |
| 81333 | <1% | 118 | $402.78 | |
| 81270 | <1% | 91 | $400.77 | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 84 | $346.60 |
| 81327 | <1% | 61 | $188.16 | |
| 81279 | <1% | 93 | $181.50 | |
| 81210 | <1% | 93 | $171.89 | |
| 81305 | <1% | 92 | $171.89 | |
| 81243 | <1% | 62 | $167.70 | |
| 81251 | <1% | 62 | $138.90 | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 1,174 | $117.30 |
| 81250 | <1% | 91 | $57.32 | |
| 81330 | <1% | 71 | $46.06 | |
| 81332 | <1% | 21 | $42.78 | |
| 81260 | <1% | 93 | $38.52 | |
| 81209 | <1% | 49 | $38.52 | |
| 80053 | Comprehensive metabolic panel | <1% | 14 | $37.68 |
| 81242 | <1% | 49 | $35.89 | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 14 | $27.72 |
| 81317 | 0% | 14 | $0.00 | |
| 81241 | 0% | 13 | $0.00 | |
| 81232 | 0% | 26 | $0.00 | |
| 81335 | 0% | 13 | $0.00 | |
| 81298 | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialAVERY, KAREN (DIRECTOR OF BILLING)
| Provider | Location | Paid |
|---|---|---|
| Etx Diagnostics LLC | Stafford, TX | $58K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.